Lajos Pusztai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2218567/publications.pdf

Version: 2024-02-01

361 papers	45,374 citations	3515 90 h-index	2116 203 g-index
370 all docs	370 docs citations	370 times ranked	42565 citing authors

#	Article	IF	Citations
1	Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1275-1281.	0.8	2,387
2	The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nature Biotechnology, 2006, 24, 1151-1161.	9.4	1,927
3	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	9.4	1,785
4	Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research, 2005, 11, 5678-5685.	3.2	1,618
5	Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020, 382, 810-821.	13.9	1,542
6	Gene-Expression Signatures in Breast Cancer. New England Journal of Medicine, 2009, 360, 790-800.	13.9	1,286
7	Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4414-4422.	0.8	1,243
8	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 2016, 34, 2460-2467.	0.8	1,185
9	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2012, 379, 633-640.	6.3	1,165
10	Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2â€“Positive Operable Breast Cancer. Journal of Clinical Oncology, 2005, 23, 3676-3685.	0.8	1,076
11	The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Antiâ€“HER-2 Therapy and Personalized Medicine. Oncologist, 2009, 14, 320-368.	1.9	986
12	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research, 2008, 68, 6084-6091.	0.4	916
13	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	15.2	823
14	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature Biotechnology, 2010, 28, 827-838.	9.4	795
15	Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet, The, 2011, 378, 1812-1823.	6.3	629
16	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4236-4244.	0.8	621
17	Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2â€“Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology, 2002, 20, 1800-1808.	0.8	564
18	The HERâ€2/ neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. Oncologist, 2003, 8, 307-325.	1.9	561

#	Article	IF	Citations
19	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 1873.	3.8	531
20	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	3.2	529
21	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal of Clinical Oncology, 2017, 35, 1049-1060.	0.8	478
22	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 2016, 375, 23-34.	13.9	467
23	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022, 386, 556-567.	13.9	444
24	Intratumor Heterogeneity: Seeing the Wood for the Trees. Science Translational Medicine, 2012, 4, 127ps10.	5.8	443
25	Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research, 2007, 13, 228-233.	3.2	434
26	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
27	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 676.	3.4	419
28	In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. Clinical Cancer Research, 2014, 20, 2773-2782.	3.2	403
29	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1508-1516.	0.7	401
30	Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. Journal of Clinical Oncology, 2005, 23, 5983-5992.	0.8	383
31	Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8315-8320.	3.3	368
32	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	13.9	363
33	Impact of Financial Burden of Cancer on Survivors' Quality of Life. Journal of Oncology Practice, 2014, 10, 332-338.	2.5	341
34	Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncology, The, 2019, 20, e175-e186.	5.1	329
35	PIK3CAmutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptorâ€“positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10208-10213.	3.3	324
36	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, 2015, 3, 326-332.	1.6	310

#	Article	IF	Citations
37	Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 2016, 375, 11-22.	13.9	301
38	Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. Clinical Cancer Research, 2009, 15, 441-451.	3.2	300
39	A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal of Medicine, 2015, 373, 503-510.	13.9	282
40	Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine, 2004, 25, 94-102.	1.4	271
41	Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104, 682-691.	2.0	267
42	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2005, 23, 8331-8339.	0.8	266
43	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	2.0	265
44	Targeted Therapy in Breast Cancer. Molecular and Cellular Proteomics, 2004, 3, 379-398.	2.5	263
45	Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Research and Treatment, 2011, 128, 783-794.	1.1	256
46	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal of Clinical Oncology, 2007, 25, 2650-2655.	0.8	253
47	Immunological differences between primary and metastatic breast cancer. Annals of Oncology, 2018, 29, 2232-2239.	0.6	238
48	Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. Oncologist, 2008, 13, 477-493.	1.9	235
49	Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal of Clinical Oncology, 2012, 30, 729-734.	0.8	231
50	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	3.0	203
51	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptorâ€“Positive and â€“Negative Cancers. Journal of Clinical Oncology, 2010, 28, 4316-4323.	0.8	193
52	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research, 2010, 16, 5351-5361.	3.2	185
53	Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse. Breast Cancer Research and Treatment, 2003, 78, 105-118.	1.1	179
54	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncology, The, 2007, 8, 203-211.	5.1	175

#	Article	IF	Citations
55	Molecular Classification of Breast Cancer: Limitations and Potential. Oncologist, 2006, 11, 868-877.	1.9	174
56	Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3185-3191.	0.8	173
57	Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer, 2003, 97, 2960-2971.	2.0	170
58	Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer, 2015, 121, 2544-2552.	2.0	162
59	Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis. Oncologist, 2010, 15, 1164-1168.	1.9	159
60	Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database. Journal of the American College of Surgeons, 2015, 220, 1063-1069.	0.2	152
61	Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clinical Cancer Research, 2003, 9, 2406-15.	3.2	152
62	Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal of Clinical Oncology, 2011, 29, 3739-3746.	0.8	151
63	Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. Cancer Research, 2009, 69, 8579-8584.	0.4	150
64	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	5.1	148
65	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology, 2022, 8, 607.	3.4	147
66	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 1816-1837.	0.8	139
67	Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. Oncologist, 2001, 6, 133-146.	1.9	137
68	Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. Annals of Surgery, 2006, 244, 464-470.	2.1	135
69	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell, 2021, 39, 989-998.e5.	7.7	131
70	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1707.	3.4	129
71	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1821-1828.	0.8	128
72	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 927-939.	0.4	128

#	Article	IF	Citations
73	New Strategies in Breast Cancer: Immunotherapy. Clinical Cancer Research, 2016, 22, 2105-2110.	3.2	124
74	Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy. Cancer Journal (Sudbury, Mass), 2003, 9, 33-41.	1.0	122
75	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	3.4	119
76	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	3.4	118
77	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. Cancer Research, 2017, 77, 3317-3324.	0.4	117
78	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nature Clinical Practice Oncology, 2006, 3, 621-632.	4.3	116
79	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology, The, 2010, 11, 358-365.	5.1	116
80	Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2007, 13, 2061-2067.	3.2	115
81	Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer, 2004, 100, 1814-1822.	2.0	110
82	Challenges translating breast cancer gene signatures into the clinic. Nature Reviews Clinical Oncology, 2012, 9, 58-64.	12.5	108
83	Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer, 2004, 100, 499-506.	2.0	107
84	Biomarker studies: a call for a comprehensive biomarker study registry. Nature Reviews Clinical Oncology, 2011, 8, 171-176.	12.5	106
85	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106
86	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
87	Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers. Journal of the National Cancer Institute, 2011, 103, 1871-1883.	3.0	104
88	CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. Cell Reports, 2019, 29, 3405-3420.e5.	2.9	104
89	Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Research and Treatment, 2005, 89, 149-157.	1.1	98
90	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology, 2020, 33, 1746-1752.	2.9	94

#	Article	IF	Citations
91	Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures. PLoS ONE, 2011, 6, e28403.	1.1	93
92	Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncology, The, 2007, 8, 55-62.	5.1	92
93	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell, 2022, 40, 609-623.e6.	7.7	92
94	Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 461-468.	1.0	91
95	The Nuclear Transcription Factor ÎºB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer. Clinical Cancer Research, 2005, 11, 8398-8402.	3.2	91
96	Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. American Journal of Surgery, 2001, 182, 601-608.	0.9	90
97	High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Research and Treatment, 2013, 137, 319-327.	1.1	90
98	Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2013, 19, 1587-1595.	3.2	90
99	Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Research and Treatment, 2014, 143, 403-409.	1.1	90
100	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research, 2017, 19, 91.	2.2	90
101	Breast cancer biomarkers and molecular medicine. Expert Review of Molecular Diagnostics, 2003, 3, 573-585.	1.5	89
102	Higher parity and shorter breastfeeding duration. Cancer, 2010, 116, 4933-4943.	2.0	88
103	Distinct tumor protein p53 mutants in breast cancer subgroups. International Journal of Cancer, 2013, 132, 1227-1231.	2.3	88
104	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptorâ€positive, HER2â€normal, grade II, lymph nodeâ€negative breast cancers. Cancer, 2010, 116, 5161-5167.	2.0	87
105	Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptorâ€“Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	87
106	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2008, 108, 183-190.	1.1	85
107	Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. , 2020, 8, e001558.		85
108	Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2003, 21, 3249-3254.	0.8	83

#	Article	IF	Citations
109	Reproducibility of research and preclinical validation: problems and solutions. Nature Reviews Clinical Oncology, 2013, 10, 720-724.	12.5	83
110	Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal of Clinical Oncology, 2015, 33, 4267-4276.	0.8	83
111	Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. Journal of Clinical Oncology, 2009, 27, 4287-4292.	0.8	81
112	CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. Breast Cancer Research, 2018, 20, 154.	2.2	80
113	Use of standard markers and incorporation of molecular markers into breast cancer therapy. Cancer, 2011, 117, 1575-1582.	2.0	77
114	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. Cell Reports, 2018, 25, 1446-1457.	2.9	76
115	Targeted therapies for cancer 2004. American Journal of Clinical Pathology, 2004, 122, 598-609.	0.4	76
116	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist, 2013, 18, 1063-1073.	1.9	75
117	Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research, 2016, 18, 78.	2.2	75
118	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Medicine, 2016, 13, e1002193.	3.9	75
119	Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research, 2010, 16, 711-718.	3.2	72
120	Agreement in Risk Prediction Between the 21â€Gene Recurrence Score Assay (Onco type DXÂ®) and the PAM50 Breast Cancer Intrinsic Classifierâ„¢ in Earlyâ€Stage Estrogen Receptorâ€“Positive Breast Cancer. Oncologist, 2012, 17, 492-498.	1.9	71
121	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	3.2	71
122	Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human cancer. Nature Communications, 2017, 8, 14929.	5.8	71
123	Clinical Application of cDNA Microarrays in Oncology. Oncologist, 2003, 8, 252-258.	1.9	70
124	The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resistance Updates, 2010, 13, 99-108.	6.5	70
125	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research, 2013, 73, 6516-6525.	0.4	70
126	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. Journal of Clinical Oncology, 2008, 26, 806-813.	0.8	68

#	Article	IF	Citations
127	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 125, 785-795.	1.1	68
128	Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2 ⁺ :ERÎ± ^{â^'} breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5832-5837.	3.3	67
129	The cell cycle regulator 14-3-3ïƒ opposes and reverses cancer metabolic reprogramming. Nature Communications, 2015, 6, 7530.	5.8	65
130	A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. Genome Medicine, 2015, 7, 104.	3.6	65
131	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. Molecular Cancer Therapeutics, 2018, 17, 1324-1331.	1.9	65
132	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. Journal of Clinical Oncology, 2016, 34, 3511-3517.	0.8	64
133	Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncology, The, 2019, 20, e390-e396.	5.1	63
134	Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. Clinical Cancer Research, 2012, 18, 1109-1119.	3.2	62
135	Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer. Clinical Cancer Research, 2007, 13, 6080-6086.	3.2	61
136	PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. Clinical Cancer Research, 2020, 26, 5456-5461.	3.2	60
137	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. Oncologist, 2009, 14, 1182-1188.	1.9	59
138	Stability of estrogen receptor status in breast carcinoma. Cancer, 2011, 117, 705-713.	2.0	59
139	TP53 mutationâ€correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53â€mutated breast cancers. Molecular Oncology, 2014, 8, 508-519.	2.1	59
140	Overall Survival of CDK4/6-Inhibitorâ€“Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1089-1097.	3.0	59
141	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research, 2010, 70, 8852-8862.	0.4	58
142	Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research, 2003, 9, 5652-9.	3.2	58
143	Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathology and Oncology Research, 2001, 7, 171-177.	0.9	56
144	Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes. Clinical Cancer Research, 2007, 13, 2831-2835.	3.2	56

#	Article	IF	Citations
145	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer, 2006, 107, 1459-1466.	2.0	55
146	Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. Journal of Clinical Oncology, 2008, 26, 2636-2643.	0.8	54
147	A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. Oncologist, 2014, 19, 453-458.	1.9	53
148	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research, 2011, 17, 2591-2601.	3.2	52
149	Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden. Nature Communications, 2020, 11, 2438.	5.8	52
150	Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. , 2019, 7, 88.		51
151	CECR2 drives breast cancer metastasis by promoting NF-Î²B signaling and macrophage-mediated immune suppression. Science Translational Medicine, 2022, 14, eabf5473.	5.8	51
152	Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer, 2005, 104, 676-681.	2.0	50
153	Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research and Treatment, 2010, 121, 301-309.	1.1	50
154	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMxÂ® Digital Spatial Profiler. Cancers, 2021, 13, 4456.	1.7	50
155	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 26-33.	3.2	49
156	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Research and Treatment, 2018, 168, 631-638.	1.1	49
157	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptorâ€“Positive Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 4380-4387.	3.2	49
158	Phase I and II Study of Exisulind in Combination With Capecitabine in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2003, 21, 3454-3461.	0.8	48
159	Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers. Oncologist, 2010, 15, 246-252.	1.9	47
160	Comparison of the Predictive Accuracy of DNA Array-Based Multigene Classifiers across cDNA Arrays and Affymetrix GeneChips. Journal of Molecular Diagnostics, 2005, 7, 357-367.	1.2	44
161	Current Status of Prognostic Profiling in Breast Cancer. Oncologist, 2008, 13, 350-360.	1.9	44
162	Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Research and Treatment, 2010, 123, 747-755.	1.1	44

#	Article	IF	Citations
163	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. Breast Cancer Research and Treatment, 2019, 175, 247-259.	1.1	43
164	Breast cancer biomarkers and molecular medicine: part II. Expert Review of Molecular Diagnostics, 2004, 4, 169-188.	1.5	42
165	Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Annals of Surgical Oncology, 2011, 18, 932-938.	0.7	42
166	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology, 2021, 7, 1654.	3.4	42
167	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist, 2016, 21, 1063-1078.	1.9	41
168	Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer, 2016, 122, 1588-1597.	2.0	40
169	Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clinical Epigenetics, 2018, 10, 112.	1.8	40
170	USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 10-17.	1.0	39
171	Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist, 2019, 24, 313-318.	1.9	39
172	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Antiâ€“PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research, 2021, 27, 5299-5306.	3.2	39
173	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 566-578.	0.4	38
174	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Global Oncology, 2021, 7, 162-172.	0.8	38
175	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. Journal of Clinical Oncology, 2022, 40, 503-503.	0.8	38
176	Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer. Cancer Investigation, 2006, 24, 187-191.	0.6	37
177	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Research and Treatment, 2011, 130, 155-164.	1.1	36
178	Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	35
179	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer, 2021, 7, 9.	2.3	35
180	Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 135, 619-627.	1.1	33

#	Article	IF	Citations
181	Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal of the National Cancer Institute, 2013, 105, 1332-1334.	3.0	33
182	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. International Journal of Molecular Sciences, 2020, 21, 1386.	1.8	33
183	The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets, 2015, 15, 652-664.	0.8	33
184	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	1.5	33
185	Reproducibility of Gene Expression Signatureâ€“Based Predictions in Replicate Experiments. Clinical Cancer Research, 2006, 12, 1721-1727.	3.2	32
186	Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals of Surgical Oncology, 2017, 24, 3073-3081.	0.7	32
187	Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2011, 129, 451-458.	1.1	31
188	Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. Breast Cancer Research and Treatment, 2015, 154, 533-541.	1.1	31
189	Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4679-4683.	0.8	30
190	Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Research and Treatment, 2013, 137, 407-416.	1.1	30
191	Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cancer Informatics, 2017, 1, 1-10.	1.0	30
192	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal of Clinical Oncology, 2019, 37, 3484-3492.	0.8	30
193	The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. BMC Cancer, 2019, 19, 1189.	1.1	30
194	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, TPS602-TPS602.	0.8	30
195	Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer. Cancer Investigation, 2004, 22, 248-256.	0.6	29
196	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research, 2007, 9, R87.	2.2	29
197	Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genomics, 2014, 15, 876.	1.2	29
198	Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. Molecular Oncology, 2014, 8, 717-727.	2.1	29

#	Article	IF	Citations
199	Unvalidated antibodies and misleading results. Breast Cancer Research and Treatment, 2014, 147, 457-458.	1.1	29
200	Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?. American Journal of Surgery, 2017, 214, 1082-1088.	0.9	29
201	Lack of association between amplification ofher-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer, 2004, 101, 258-263.	2.0	28
202	Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. Molecular Cancer Therapeutics, 2010, 9, 1120-1127.	1.9	28
203	Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of Î²III-Tubulin Expression as a Predictive Marker. Oncologist, 2013, 18, 787-794.	1.9	28
204	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research, 2014, 20, 5265-5271.	3.2	28
205	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer, 2015, 113, 1003-1009.	2.9	28
206	New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer. Seminars in Oncology, 2007, 34, S10-S16.	0.8	27
207	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2015, 152, 95-117.	1.1	27
208	Chips to Bedside: Incorporation of Microarray Data into Clinical Practice. Clinical Cancer Research, 2006, 12, 7209-7214.	3.2	26
209	Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer. Clinical Cancer Research, 2007, 13, 4078-4082.	3.2	26
210	Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research and Treatment, 2013, 137, 631-636.	1.1	26
211	Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer. Clinical Cancer Research, 2017, 23, 1193-1199.	3.2	26
212	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. British Journal of Cancer, 2018, 118, 1107-1114.	2.9	26
213	Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Research and Treatment, 2018, 170, 55-67.	1.1	25
214	Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer, 2006, 106, 42-50.	2.0	24
215	Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Research and Treatment, 2018, 172, 105-112.	1.1	24
216	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research, 2019, 21, 72.	2.2	24

#	Article	IF	Citations
217	Immunological Differences Between Immune-Rich Estrogen Receptorâ€“Positive and Immune-Rich Triple-Negative Breast Cancers. JCO Precision Oncology, 2020, 4, 767-779.	1.5	23
218	Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. , 2021, 9, e002230.		23
219	Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nature Clinical Practice Oncology, 2004, 1, 44-50.	4.3	22
220	Predictive and Prognostic Value of the TauProtein in Breast Cancer. Anticancer Research, 2015, 35, 5179-84.	0.5	22
221	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. , 1999, 82, 525-531.		21
222	Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. Clinical Cancer Research, 2013, 19, 2817-2823.	3.2	21
223	Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals of Surgery, 2017, 265, 39-44.	2.1	21
224	LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer, 2022, 3, 355-370.	5.7	21
225	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research and Treatment, 2021, 188, 249-258.	1.1	20
226	A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. PLoS ONE, 2012, 7, e49529.	1.1	20
227	Breast Cancer Biomarkers. Advances in Clinical Chemistry, 2005, 40, 99-125.	1.8	19
228	Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2â€positive breast cancer using an LCâ€MALDIâ€TOF/MS procedure. Proteomics, 2010, 10, 3525-3532.	1.3	19
229	Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. Scientific Reports, 2019, 9, 14934.	1.6	19
230	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Oncologist, 2020, 25, 943-953.	1.9	19
231	Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. Npj Breast Cancer, 2021, 7, 60.	2.3	19
232	Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model. Acta OncolÃ³gica, 1998, 37, 629-640.	0.8	18
233	Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer, 2012, 118, 1221-1227.	2.0	18
234	Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 316-323.	1.1	18

#	Article	IF	Citations
235	Integrated MicroRNAâ€“mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 194.	1.8	18
236	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers, 2021, 13, 4839.	1.7	18
237	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research, 2020, 80, CT011-CT011.	0.4	18
238	Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics, 2004, 5, 451-454.	0.6	17
239	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncology, The, 2011, 12, 1162-1168.	5.1	17
240	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptorâ€“Positive Breast Cancer: Clinical Versus Molecular Tools. Journal of Clinical Oncology, 2019, 37, 1365-1369.	0.8	17
241	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	1.7	17
242	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. Drug Resistance Updates, 2004, 7, 325-331.	6.5	16
243	Gene expression profiling of primary breast cancer. Current Oncology Reports, 2005, 7, 38-44.	1.8	16
244	Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage Iâ€“III HER2-positive breast cancer. Breast Cancer Research and Treatment, 2018, 169, 333-340.	1.1	16
245	The impact of communication style on patient satisfaction. Breast Cancer Research and Treatment, 2019, 176, 349-356.	1.1	16
246	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	1.9	16
247	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2587-2597.	3.2	16
248	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	1.2	15
249	Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research, 2021, 23, 14.	2.2	15
250	High-dose chemotherapy: how resistant is breast cancer?. Drug Resistance Updates, 1998, 1, 62-72.	6.5	14
251	Molecular profiles of invasive mucinous and ductal carcinomas of the breast. Cancer Genetics and Cytogenetics, 2003, 141, 148-153.	1.0	14
252	Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS ONE, 2015, 10, e0119230.	1.1	14

#	Article	IF	Citations
253	The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. SpringerPlus, 2015, 4, 36.	1.2	14
254	Functional germline variants as potential co-oncogenes. Npj Breast Cancer, 2017, 3, 46.	2.3	14
255	Systematic Approach to Providing Breast Cancer Survivors With Survivorship Care Plans: A Feasibility Study. Journal of Oncology Practice, 2015, 11, e170-e176.	2.5	13
256	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology, 2018, 4, e181564.	3.4	13
257	Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options in Oncology, 2021, 22, 79.	1.3	13
258	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer, 2021, 7, 131.	2.3	13
259	Preoperative Systemic Chemotherapy and Pathologic Assessment of Response. Pathology and Oncology Research, 2008, 14, 169-171.	0.9	12
260	Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. Journal of Oncology Practice, 2017, 13, e505-e515.	2.5	12
261	Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells. Cancers, 2020, 12, 2551.	1.7	12
262	Diverse immune response of DNA damage repair-deficient tumors. Cell Reports Medicine, 2021, 2, 100276.	3.3	12
263	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 6156-6163.	3.2	12
264	Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy. Pharmaceutical Research, 2006, 23, 1951-1958.	1.7	11
265	Dynamic classification using caseâ€specific training cohorts outperforms static gene expression signatures in breast cancer. International Journal of Cancer, 2015, 136, 2091-2098.	2.3	11
266	Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. European Journal of Cancer Prevention, 2016, 25, 3-8.	0.6	11
267	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer, 2019, 118, 1-9.	1.3	11
268	Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Research and Treatment, 2019, 176, 261-270.	1.1	11
269	A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.. Journal of Clinical Oncology, 2020, 38, TPS604-TPS604.	0.8	11
270	Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. Oncotarget, 2016, 7, 22064-22076.	0.8	10

#	Article	IF	Citations
271	Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women WithERBB2(HER2)â€“Positive Breast Cancer. JAMA Network Open, 2020, 3, e2027074.	2.8	10
272	Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer, 2005, 12, 73-85.	1.3	9
273	Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. Breast Cancer Research and Treatment, 2009, 117, 325-331.	1.1	9
274	Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer. Genomics Data, 2014, 2, 354-356.	1.3	9
275	Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine. Biomarkers in Medicine, 2015, 9, 1265-1272.	0.6	9
276	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	1.2	9
277	Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. Clinical Cancer Research, 2020, 26, 1977-1984.	3.2	9
278	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clinical Cancer Research, 2021, 27, 6115-6123.	3.2	9
279	RefSeq Refinements of UniGene-Based Gene Matching Improve the Correlation of Expression Measurements Between Two Microarray Platforms. Applied Bioinformatics, 2006, 5, 89-98.	1.7	8
280	Paclitaxel-induced sickle cell crisis. American Journal of Health-System Pharmacy, 2008, 65, 1333-1336.	0.5	8
281	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management, 2019, 8, BMT22.	0.2	8
282	The Way of the Future: Personalizing Treatment Plans Through Technology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 12-23.	1.8	8
283	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Medicine, 2021, 13, 70.	3.6	8
284	Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clinical Epigenetics, 2022, 14, 30.	1.8	8
285	Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.. Journal of Clinical Oncology, 2022, 40, 504-504.	0.8	8
286	Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics, 2007, 8, 1443-1448.	0.6	7
287	Breast cancer prognostic markers in the post-genomic era. Breast Cancer Research and Treatment, 2011, 125, 647-650.	1.1	7
288	Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Cancer Research, 2020, 80, PD1-01-PD1-01.	0.4	7

#	Article	IF	Citations
289	Network propagation-based prioritization of long tail genes in 17 cancer types. Genome Biology, 2021, 22, 287.	3.8	7
290	Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials. Oncologist, 2010, 15, 476-483.	1.9	6
291	Adjuvant therapy in stage I carcinoma of the breast. Cancer, 2012, 118, 2031-2038.	2.0	6
292	A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Research and Treatment, 2013, 138, 691-698.	1.1	6
293	Computing Molecular Signatures as Optima of a Bi-Objective Function: Method and Application to Prediction in Oncogenomics. Cancer Informatics, 2015, 14, CIN.S21111.	0.9	6
294	Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints. Biometrics, 2017, 73, 687-695.	0.8	6
295	Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. Journal of Oncology Practice, 2017, 13, e1012-e1020.	2.5	6
296	Identification of a novel MYOC variant in a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure. Journal of Physical Education and Sports Management, 2019, 5, a004374.	0.5	6
297	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. BMC Cancer, 2021, 21, 114.	1.1	6
298	CCR 20th Anniversary Commentary: Divide and Conquerâ€"Breast Cancer Subtypes and Response to Therapy. Clinical Cancer Research, 2015, 21, 3575-3577.	3.2	5
299	Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 56-64.	1.8	5
300	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	3.2	5
301	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01.	0.4	5
302	Relapse after complete response to anthracyclineâ€based combination chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 1999, 55, 1-8.	1.1	4
303	Uncertainty estimation with a finite dataset in the assessment of classification models. Computational Statistics and Data Analysis, 2012, 56, 1016-1027.	0.7	4
304	Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. Breast Cancer Research and Treatment, 2014, 144, 561-568.	1.1	4
305	Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Research and Treatment, 2015, 149, 789-797.	1.1	4
306	Comparison of Residual Riskâ€"Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology, 2018, 4, e175092.	3.4	4

#	Article	IF	Citations
307	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptorâ€“positive Breast Cancer, SWOG S1222. Clinical Cancer Research, 2022, 28, 611-617.	3.2	4
308	Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Npj Breast Cancer, 2022, 8, 29.	2.3	4
309	Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research, 2022, 82, 1698-1711.	0.4	4
310	Tumor profiling and the incidentalome: patient decisions and risks. Future Oncology, 2015, 11, 3299-3305.	1.1	3
311	Chemotherapy and the recurrence scoreâ€”results as expected?. Nature Reviews Clinical Oncology, 2015, 12, 690-692.	12.5	3
312	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. Breast Cancer Research and Treatment, 2016, 155, 223-234.	1.1	3
313	Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. Journal of Cancer Research and Clinical Oncology, 2018, 144, 601-606.	1.2	3
314	Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade. JCO Precision Oncology, 2019, 3, 1-6.	1.5	3
315	Genomic Determinants of Homologous Recombination Deficiency across Human Cancers. Cancers, 2021, 13, 4572.	1.7	3
316	Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a caseâ€“control study. Breast Cancer Research, 2021, 23, 113.	2.2	3
317	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. Cancer Chemotherapy and Pharmacology, 1999, 43, 86-91.	1.1	2
318	Characterization of DNA variants in the human kinome in breast cancer. Scientific Reports, 2015, 5, 14736.	1.6	2
319	Development of Pharmacogenomic Predictors for Preoperative Chemotherapy of Breast Cancer. Advances in Experimental Medicine and Biology, 2006, 587, 233-249.	0.8	2
320	Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.. Journal of Clinical Oncology, 2015, 33, 1009-1009.	0.8	2
321	Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.. Journal of Clinical Oncology, 2015, 33, 1091-1091.	0.8	2
322	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. SSRN Electronic Journal, 0, , .	0.4	2
323	Survival outcomes in HER2-positive invasive lobular breast carcinoma.. Journal of Clinical Oncology, 2012, 30, 612-612.	0.8	2
324	Cancer Relevance of Human Genes. Journal of the National Cancer Institute, 2022, 114, 988-995.	3.0	2

#	Article	IF	Citations
325	Personalized medicine for breast cancer: moving forward and going back. Personalized Medicine, 2006, 3, 363-370.	0.8	1
326	An adaptive feature selection method for microarray data analysis. , 2012, , .		1
327	Clinical Utility of Biomarker Tests in Decisions on Extended Endocrine Therapy. Journal of Clinical Oncology, 2016, 34, 3942-3943.	0.8	1
328	TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumorâ€™s Genetic Defects to Therapeutic Options. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	1
329	Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer. Cancer Cell, 2020, 38, 323-325.	7.7	1
330	Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.. Journal of Clinical Oncology, 2017, 35, 1021-1021.	0.8	1
331	The use of microarray technology in the management of breast cancer. Clinical Advances in Hematology and Oncology, 2007, 5, 193-4, 197.	0.3	1
332	Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors. Cancer Research, 2022, 82, P1-05-02-P1-05-02.	0.4	1
333	Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). Cancer Research, 2022, 82, OT1-12-04-OT1-12-04.	0.4	1
334	Abstract P5-17-01: Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models. Cancer Research, 2022, 82, P5-17-01-P5-17-01.	0.4	1
335	Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221.. Journal of Clinical Oncology, 2022, 40, 12023-12023.	0.8	1
336	Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.. Journal of Clinical Oncology, 2022, 40, 3535-3535.	0.8	1
337	Individualized therapy of breast cancer: are we there yet?. Personalized Medicine, 2008, 5, 557-559.	0.8	0
338	New targets in breast cancer. Memo - Magazine of European Medical Oncology, 2015, 8, 86-91.	0.3	0
339	Discussion of: â€œDoes lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?â€• American Journal of Surgery, 2017, 214, 1089-1090.	0.9	0
340	Reply to S. Romero-Cordoba et al. JCO Precision Oncology, 2020, 4, 1269-1270.	1.5	0
341	Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials. Contemporary Clinical Trials, 2021, 110, 106589.	0.8	0
342	A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3119-TPS3119.	0.8	0

#	Article	IF	Citations
343	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 530-530.	0.8	0
344	Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.. Journal of Clinical Oncology, 2014, 32, 2561-2561.	0.8	0
345	Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 1065-1065.	0.8	0
346	A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.. Journal of Clinical Oncology, 2015, 33, 578-578.	0.8	0
347	Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.. Journal of Clinical Oncology, 2015, 33, 538-538.	0.8	0
348	Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).. Journal of Clinical Oncology, 2015, 33, 1012-1012.	0.8	0
349	A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).. Journal of Clinical Oncology, 2015, 33, 6621-6621.	0.8	0
350	Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.. Journal of Clinical Oncology, 2015, 33, e12564-e12564.	0.8	0
351	Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers.. Journal of Clinical Oncology, 2015, 33, 1081-1081.	0.8	0
352	Discovery and disclosure of incidental genetic information obtained through high throughput sequencing.. Journal of Clinical Oncology, 2015, 33, e17779-e17779.	0.8	0
353	T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.. Journal of Clinical Oncology, 2016, 34, 585-585.	0.8	0
354	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. Journal of Clinical Oncology, 2020, 38, 511-511.	0.8	0
355	323â€...Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients. , 2020, , .		0
356	Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Cancer Research, 2022, 82, PD5-05-PD5-05.	0.4	0
357	Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG) Tj ETQq1 1 0.784314 rgBT /Over Oncology, 2022, 40, 594-594.	0.8	0
358	Treatment patterns and medical costs of metastatic breast cancer care in the United States.. Journal of Clinical Oncology, 2022, 40, e18834-e18834.	0.8	0
359	Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.. Journal of Clinical Oncology, 2022, 40, 516-516.	0.8	0
360	The mutational profile of ER-, PR+, HER2- metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1025-1025.	0.8	0

#	Article	IF	Citations
361	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.. Journal of Clinical Oncology, 2022, 40, 12084-12084.	0.8	0